Accelerate to discover

Back to filter

Related topics

Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer

Agilent technologies

Nov 23, 2021

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...

Discover the advanced Detector Technology in Agilent NovoCyte flow cytometers

Agilent technologies

Nov 8, 2021

This technical overview describes advancements in detector technology, and highlights examples where optimal signal...

Jan 18, 2022

X-ray-virus-inactivation

Precision X-Ray

Oct 20, 2021

Ionizing radiation approaches are effective but use of radioactive radioisotopic elements have become difficult to...

Duke uses XRAD 225 CX to test radiosensitivity hypothesis

Precision X-Ray

Oct 18, 2021

Image guided radiotherapy in a preclinical setting couldn’t be more useful than the treatment of brain tumors, where...

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

Jan 18, 2022

Falling in love with Magnetic resonance

Bruker Biospin

Oct 4, 2021

Magnetic Resonance (MR) is more than just analytical science, it is unique, it is a passion that won’t let you go

Show all topics (10)

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Jun 1, 2018

The 10‐year survival rate of cancer patients has greatly increased over the last 20 years. However, the survival rate of patients with major malignant tumors, such as lung and pancreatic cancers, still shows negligible improvement.The conventional chemotherapeutic strategy for treating lung cancer remains unsatisfactory in this respect. Specifically, the 5‐year survival rates of both non‐small‐cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients exhibited merely 4–5% improvements in the past decade for cancer in stages I–III.2 The main difficulty in treating lung cancer is the lack of targeted chemotherapeutic agents specific to the lung tumor tissues and, thus, non‐specific targeting generally leads to unwanted side effects induced by excessive doses of chemotherapeutic agents.

Several strategies have been introduced to resolve the aforementioned issues, such as cancer antigen‐targeted monoclonal antibody (mAb) therapy,4 nanodrug delivery,5 and cell‐mediated therapy (i.e., T‐cell‐based therapy for NSCLC6). However, many clinical trials have shown that intravenously administered mAb, particularly epidermal growth factor receptor‐targeting mAbs, induced dermatological toxicities (e.g., acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, and hair/nail changes) in over 50% of patients after treatment.

Read more!

Scientific paper
Application

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Yokogawa

Yokogawa is a leading provider of confocal quantitative live cell imaging platforms. Combining superior technology with engineering services, project management, and maintenance, Yokogawa delivers field proven operational efficiency, safety, quality, and reliability. 

Related products

Confocal quantitative image cytometer CQ1 offers a new approach to image quantification

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey